Gilead Sciences

Gilead Sciences

Yahoo Finance • yesterday

Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive?

Gilead Sciences, Inc. (NASDAQ:GILD) has had a considerably better year than the broader market. The stock has surged by over 24% since the start of the year, compared with a 14% return for the S&P 500. The rally has changed the valuation e... Full story

Yahoo Finance • 5 days ago

Is Extending the Gilead E3 Ligase Collaboration Altering The Investment Case For Nurix Therapeutics (NRIX)?

Nurix Therapeutics, Inc. recently announced that it has extended by two years the research term for an undisclosed oncology program under its ongoing collaboration with Gilead Sciences, originally established in 2019 to develop E3 ligase–b... Full story

Yahoo Finance • 5 days ago

Is Abbott Laboratories (ABT) a Dividend Bargain After Its 2026 Selloff?

Abbott Laboratories (NYSE:ABT) is a business that is not showcasing any rapid growth trends. However, what makes it an attractive investment prospect is the company's consistent track record of incremental dividends, with 411 consecutive q... Full story

Yahoo Finance • 5 days ago

U.S. equities tumble while Treasury yields push higher

[Wall Street New York stock exchange stock market] alexsl U.S. equities traded to the downside on Wednesday as investors looked forward to the release of the Federal Reserve's latest meeting minutes later in the day. The blue-chip Dow (D... Full story

Yahoo Finance • 7 days ago

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

Nurix Therapeutics, Inc. Two-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE, Calif., Oct... Full story

Yahoo Finance • 10 days ago

Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says

Legend Biotech's (LEGN) multiple myeloma therapy Carvykti is facing growing competitive pressure as PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 12 days ago

Pharmaceutical industry lobbying group names new CEO, Eric Cantor

[Cantor And John Thune Hold Press Conference On Economy] Alex Wong/Getty Images News * The Pharmaceutical Research and Manufacturers of America (PhRMA) has selected former Republican House Majority Leader Eric Cantor as its next CEO and... Full story

Yahoo Finance • 12 days ago

CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J

Company Logo The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding c... Full story

Yahoo Finance • 13 days ago

Stocks making the biggest moves premarket: Fair Isaac, SpaceX, AMD & more

Check out the companies making the biggest moves premarket: Fair Isaac — Shares plunged 18% after Federal Housing Finance Agency director Bill Pulte introduced changes to mortgage pricing. "We are Simplifying Mortgage Pricing following fee... Full story

Yahoo Finance • 13 days ago

Small Molecule Drug Discovery - Global Strategic Business Report Forecasts Growth from $61.5B (2024) to $100B by 2030, Profiling AstraZeneca, Gilead Sciences, Merck & Pfizer

Company Logo AI, computational design and high-throughput screening are accelerating discovery, while targeted therapies, outsourcing and Asia-Pacific expansion create opportunities. Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Small Mole... Full story

Yahoo Finance • 14 days ago

Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase?

On September 16, Gilead Sciences, Inc. (NASDAQ:GILD) expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to cover an investigational once-yearly formulation for HIV pre-exposure prophylaxis (PrEP). Cov... Full story

Yahoo Finance • 15 days ago

Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income?

Gilead Sciences, Inc. (NASDAQ:GILD) and Medtronic plc (NYSE:MDT) both combine growing healthcare businesses with regular cash returns to shareholders, but the sources of that growth look very different. Gilead is being propelled by its do... Full story

Yahoo Finance • 15 days ago

Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?

Gilead Sciences, Inc. (NASDAQ:GILD) and Abbott Laboratories (NYSE:ABT) both return cash to shareholders through dividends, but the businesses supporting those payouts look very different. Gilead is currently growing faster, powered by an... Full story

Yahoo Finance • 15 days ago

Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification?

Gilead Sciences, Inc. (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ) offer investors two very different versions of pharmaceutical growth. Gilead is expanding faster, powered by an HIV franchise that continues to gain momentum, while Johns... Full story

Yahoo Finance • 15 days ago

Gilead’s HIV Concentration or Pfizer’s Patent Cliff: Which Risk is Easier to Own?

Pfizer Inc. (NYSE:PFE) and Gilead Sciences, Inc. (NASDAQ:GILD) present investors with two very different forms of concentration risk. Pfizer needs newer medicines and its pipeline to offset revenue that will increasingly face generic and b... Full story

Yahoo Finance • 18 days ago

Barron's 400 ETF (BFOR) Adds Energy and Materials, Reduces Utilities and Consumer Discretionary in Fall Rebalance

DENVER, September 24, 2026--(BUSINESS WIRE)--The Barron's 400 ETF (NYSE Arca: BFOR, the "Fund"), a smart beta exchange-traded fund, has completed its semi-annual rebalance following the reconstitution and equal weighting of its underlying... Full story

Yahoo Finance • 20 days ago

Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)

Reflecting On Therapeutics Stocks' Q2 Earnings: AbbVie (NYSE:ABBV) Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look at AbbVie (NYSE:ABBV) and its peers. Over the... Full story

Yahoo Finance • 20 days ago

1 Cash-Producing Stock on Our Buy List and 2 We Find Risky

1 Cash-Producing Stock on Our Buy List and 2 We Find Risky Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to m... Full story

Yahoo Finance • 21 days ago

Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers

This article first appeared on GuruFocus. Novo Nordisk A/S (NYSE:NVO) shares fell 5.96% in Copenhagen trading, as the Danish drugmaker used its London Capital Markets Day to lay out 2030 strategic ambitions, the first full reset under new... Full story

Yahoo Finance • 21 days ago

Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig

Key Points Interested in Lakefront Biotherapeutics American Depositary Shares? Here are five stocks we like better. Lakefront plans to start registrational trials for gamgertamig in ITP and AIHA in 2027, with additional autoimmune basket... Full story